COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021
10.24171/j.phrp.2021.0310
- Author:
Insob HWANG
1
;
Kyeongeun PARK
;
Tae Eun KIM
;
Yunhyung KWON
;
Yeon-Kyeng LEE
Author Information
1. Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea
- Publication Type:Brief Report
- From:
Osong Public Health and Research Perspectives
2021;12(6):396-402
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an analysis of the characteristics of suspected adverse event cases for each type of vaccine.
Methods:Adverse events following COVID-19 vaccination reported by medical doctors and forensic pathologists were analyzed. Cases of suspected anaphylaxis were classified using the Brighton Collaboration definition.
Results:By October 31, 2021, a total of 353,535 (0.45%) adverse events were reported after 78,416,802 COVID-19 vaccine doses. Of the adverse events, 96.4% were non-serious and 3.6% were serious. The most frequently reported adverse events were headache, myalgia, and dizziness. Of the 835 reported deaths after COVID-19 vaccination, 2 vaccine-related deaths were confirmed. Suspected anaphylaxis was confirmed in 454 cases using the Brighton Collaboration definition.
Conclusion:The commonly reported symptoms were similar to those described in clinical trials. Most reported adverse events were non-serious, and the reporting rate of adverse events following COVID-19 vaccination was higher in women than in men (581 vs. 315 per 100,000 vaccinations). Confirmed anaphylaxis was reported in 5.8 cases per 1,000,000 vaccinations.
